Same Indication

Ipilimumab vs Montelukast

Ipilimumab vs Montelukast: Overview

This comparison examines the pharmacological differences between Ipilimumab and Montelukast.

Mechanism of Action

Ipilimumab: Fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 inhibitory signaling.

Montelukast: Selective leukotriene D4 receptor antagonist.

Pharmacokinetics

Half-life: Ipilimumab — 14.7 days; Montelukast — 2.7-5.5 hours.

Chemical Properties

Molecular Formula: Montelukast — C35H36ClNO3S.

Molecular Weight: Montelukast — 586.1800 g/mol.

Type: Ipilimumab — Antibody; Montelukast — Small molecule.